Zevra Therapeutics (ZVRA) Finished Goods (2023 - 2024)

Zevra Therapeutics' (ZVRA) quarterly Finished Goods came in at $1.1 million in Q3 2024, down 45.35% on a QoQ basis from $2.1 million in Q2 2024.

Zevra Therapeutics (ZVRA) Finished Goods (2023 - 2024) Analysis & Trends

Zevra Therapeutics (ZVRA) has 2 years of Finished Goods data on file, last reported at $1.1 million in Q3 2024.

Quarterly Finished Goods changed N/A year-over-year to $1.1 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.1 million (changed N/A YoY) and the FY2023 annual result came in at $5.0 million, changed N/A from the prior year.
Finished Goods declined to $1.1 million in Q3 2024, from $2.1 million in the prior quarter.
In the past five years, Finished Goods ranged from a high of $5.1 million in Q1 2024 to a low of $1.1 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Zevra Therapeutics	671.75 Mn	450.18 Mn	38.18 Mn

Download Data